(Reuters) -Capricor Therapeutics said on Tuesday the U.S. Food and Drug Administration will not convene its panel of outside experts before deciding on the company’s cell therapy for a heart condition associated with Duchenne muscular dystrophy.
(Reporting by Mariam Sunny in Bengaluru)
